



Conquering hepatitis C in our time

XTLbio ADRs to Commence Trading on US NASDAQ National Market

Rehovot, Israel, 1 September 2005: XTL Biopharmaceuticals Ltd. (LSE: XTL) (XTLbio) announced that it has completed the registration process for its shares with the US Securities and Exchange Commission and that its shares are scheduled to begin trading today Thursday 1 September 2005 on the US NASDAQ National Market under the ticker symbol "XTLB". Trading will be in the form of American Depository Receipts ("ADRs"), each ADR representing ten (10) ordinary shares. Depository bank for the ADR program is the Bank of New York.

Michael S. Weiss, Chairman of XTLbio, commented: "We are very pleased to join the ranks of the leading biotechnology companies that are traded on the NASDAQ. We believe that this is a major milestone for the Company and will help us attract US investors and analysts."

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer

Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing drugs against hepatitis. Established in 1993, XTLbio became a public company in 2000 and its ordinary shares are listed on the Official List of the UK Listing Authority and are traded on the London Stock Exchange under the symbol XTL, on the Tel Aviv Stock Exchange, Israel and on NASDAQ under the symbol XTLB.

Cautionary Statement

Some of the statements included in this press release may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the U.S. Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially, and therefore affect interest by investors in our ADR's, are the following: our ability to successfully complete cost-effective clinical trials for the drug candidates in our pipelines and other risk factors identified from time to time in our reports filed with the regulatory authorities in Israel, the United Kingdom and the United States. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not intend to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.xtlbio.com. The information in our website is not incorporated by reference into this press release and is included as an inactive textual reference only.